On 4 June, 2021, Pharmaxis (ASX: PXS) hosted an investor briefing with CEO Gary Phillips to update investors on recent achievements and future plans, plus a Q&A with attendees.
Topics discussed in the briefing and question time included:
Company Summary
Pharmaxis is in a rare microcap air for a pharmaceutical research company that has a commercialised product at market with sales nearing profitability that can fund transformational cancer research. Addressing a substantial market opportunity through targeting of myelofibrosis where current treatment standards are limited, yet still sell upwards of USD $1 billion per year.
In May 2021, Emerald Financial published a research report on Pharmaxis which can be downloaded here.
Atomo Diagnostics (ASX:AT1) has secured a significant new order for its patented Pascal cassette, with…
The June 2025 quarter CPI data released today were cheered by mortgage holders and share…
AI Gains Ground in Defence Sector As governments increase investment in defence technology, AI-powered tools…
Calix Limited (ASX:CXL) has taken a significant leap forward in developing Australia’s low-emissions steel value…
Online tech retailer Harris Technology (ASX: HT8) has delivered a strong lift in gross product…
In a significant move set to reshape rapid diagnostics in the U.S., ASX-listed Lumos Diagnostics…